Product Introduction
Bioactivity


英文名: Zabicipril

描述: Zabicipril 是一种新型可口服的血管紧张转换酶抑制剂，是一种前药，在体内脱酯后具有抗高血压活性。

体内活性: We have investigated the acute effects of Zabicipril on systemic and renal haemodynamics in two groups of 8 sodium-replete normal men, aged 23 to 30 y and 65 to 74 y. Zabicipril 0.5 mg, 1 mg or 2.5 mg and a placebo were administered orally, at one-week intervals, in random order and in a double-blind fashion. Haemodynamic measurements were performed at baseline and every hour for 4 hours after intake of the drug or placebo. In the young men, zabicipril did not affect Q, heart rate (HR), systemic arterial pressure (AP) or GFR, but it did increase RPF at the 4th hour after the highest dose (from 540 to 653 ml.min-1.m-2). In the old men, zabicipril had similar actions, but the effect of the highest dose on RPF (from 355 to 415 ml.min-1.m-2) was less marked than in the young men. In the young and old men, the inhibition of ACE peaked at about 90% or more from the 2nd to the 4th hour after the highest dose of zabicipril. We conclude that, in normal men, zabicipril increases the renal fraction of cardiac output in the absence of a concomitant change in systemic haemodynamics. This specific effect of zabicipril on the kidney may be less important with advancing age.[1]

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 55 mg/mL (132.05 mM)


相关产品: L162441 | MLN-4760 | Azilsartan | Rentiapril | Temocapril hydrochloride | Allisartan Isoproxil | Aliskiren D6 hemifumarate | Quinapril hydrochloride | Lisinopril dihydrate | Buloxibutid

相关库: Membrane Protein-targeted Compound Library | Bioactive Compounds Library Max | Inhibitor Library | Bioactive Compound Library